Modeling the structure and DAP5-binding site of the FGF-9 5′-UTR RNA utilized in cap-independent translation
- PhD Program in Biochemistry, The Graduate Center, CUNY, New York, New York 10016, USA
- Department of Chemistry, Hunter College, CUNY, New York, New York 10065, USA
- Corresponding author: dgoss{at}hunter.cuny.edu
-
Handling editor: Adrian Ferre-D'Amare
Abstract
Cap-independent or eukaryotic initiation factor (eIF) 4E-independent, translation initiation in eukaryotes requires scaffolding protein eIF4G or its homolog, death-associated protein 5 (DAP5). eIF4G associates with the 40S ribosomal subunit, recruiting the ribosome to the RNA transcript. A subset of RNA transcripts, such as fibroblast growth factor 9 (FGF-9), contain 5′ untranslated regions (5′ UTRs) that directly bind DAP5 or eIF4GI. For viral mRNA, eIF recruitment usually utilizes RNA structure, such as a pseudoknot or stem–loops, and the RNA-helicase eIF4A is required for DAP5- or 4G-mediated translation, suggesting these 5′ UTRs are structured. However, for cellular IRES-like translation, no consensus RNA structures or sequences have yet been identified for eIF binding. However, the DAP5-binding site within the FGF-9 5′ UTR is unknown. Moreover, DAP5 binds to other, dissimilar 5′ UTRs, some of which require an unpaired, accessible 5′ end to stimulate cap-independent translation. Using SHAPE-seq, we modeled the 186 nt FGF-9 5′-UTR RNA's complex secondary structure in vitro. Further, DAP5 footprinting, toeprinting, and UV cross-linking experiments identify DAP5–RNA interactions. Modeling of FGF-9 5′-UTR tertiary structure aligns DAP5-interacting nucleotides on one face of the predicted structure. We propose that RNA structure involving tertiary folding, rather than a conserved sequence or secondary structure, acts as a DAP5-binding site. DAP5 appears to contact nucleotides near the start codon. Our findings offer a new perspective in the hunt for cap-independent translational enhancers. Structural, rather than sequence-specific, eIF-binding sites may act as attractive chemotherapeutic targets or as dosage tools for mRNA-based therapies.
Keywords
Footnotes
-
Article is online at http://www.rnajournal.org/cgi/doi/10.1261/rna.080013.124.
- Received February 28, 2024.
- Accepted May 28, 2024.
This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.










